Aurinia Pharmaceuticals Inc. Share Price Toronto S.E.
Equities
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 23Cr 0 1.9TCr | Sales 2025 * | 28Cr 0 2.36TCr | Capitalization | 83Cr 0 6.91TCr |
---|---|---|---|---|---|
Net income 2024 * | 90L - 75Cr | Net income 2025 * | 7.1Cr - 592.96Cr | EV / Sales 2024 * | 1.9 x |
Net cash position 2024 * | 40Cr 0 3.3TCr | Net cash position 2025 * | 45Cr 0 3.74TCr | EV / Sales 2025 * | 1.34 x |
P/E ratio 2024 * |
100
x | P/E ratio 2025 * |
12.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.93% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16/93/16 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29/19/29 |
Robert Foster
FOU | Founder | 65 | 16/93/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16/93/16 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26/19/26 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29/19/29 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.77TCr | |
-17.74% | 2.03TCr | |
-15.17% | 1.68TCr | |
-15.21% | 1.56TCr | |
+11.91% | 1.48TCr | |
-47.10% | 1.46TCr | |
+54.50% | 1.44TCr |